Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Capital Expenditures (2019 - 2025)

Historic Capital Expenditures for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to $71000.0.

  • Summit Therapeutics' Capital Expenditures rose 2241.38% to $71000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $507000.0, marking a year-over-year increase of 29921.26%. This contributed to the annual value of $139000.0 for FY2024, which is 859.38% up from last year.
  • According to the latest figures from Q3 2025, Summit Therapeutics' Capital Expenditures is $71000.0, which was up 2241.38% from $422000.0 recorded in Q1 2025.
  • Summit Therapeutics' Capital Expenditures' 5-year high stood at $422000.0 during Q1 2025, with a 5-year trough of -$20000.0 in Q3 2022.
  • For the 5-year period, Summit Therapeutics' Capital Expenditures averaged around $93888.9, with its median value being $53000.0 (2023).
  • In the last 5 years, Summit Therapeutics' Capital Expenditures plummeted by 40000.0% in 2022 and then soared by 1045000.0% in 2025.
  • Quarter analysis of 5 years shows Summit Therapeutics' Capital Expenditures stood at $120000.0 in 2021, then plummeted by 108.33% to -$10000.0 in 2022, then soared by 120.0% to $2000.0 in 2023, then surged by 600.0% to $14000.0 in 2024, then soared by 407.14% to $71000.0 in 2025.
  • Its last three reported values are $71000.0 in Q3 2025, $422000.0 for Q1 2025, and $14000.0 during Q4 2024.